Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world study of bevacizumab + TAS-102 in third-line or later metastatic colorectal cancer
ChiCTR2200064985Phase 2Recruiting
- Sponsor
- Fujian Medical University Union Hospital
- Start
- Nov 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab and trifluridine + tipiracil in colorectal cancer (CRC) and metastatic colorectal adenocarcinoma (mCRC), sponsored by Fujian Medical University Union Hospital. Primary endpoints: overall survival and progression-free survival. Started Nov 2022; status: recruiting.
02
Drugs
bevacizumabtrifluridine + tipiracil
03
Conditions
colorectal cancer (CRC)metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on ChiCTR2200064985.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200064985.